21:55 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

Transient nanotargeting

A team from the Fred Hutchinson Cancer Research Center has designed nanoparticles that introduce mRNA cargo to therapeutic cells in vitro, without requiring special instrumentation or causing the cell depletion or cytotoxicity that limits the...
07:00 , Jun 23, 2016 |  BC Innovations  |  Translation in Brief

Musashi's dual duel

The Musashi genes were originally named for the samurai who fought with two swords because, when discovered in flies, their mutation created double-shafted bristles. Now, a pair of studies double down on the name, showing...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Tumor levels of Musashi homolog 2 (MSI2) as diagnostic marker for aggressive non-small cell lung cancer (NSCLC)

Biomarkers TECHNOLOGY: Tissue markers Tumor levels of MSI2 could help diagnose aggressive NSCLC. In human metastatic cell lines, MSI2 mRNA levels were higher than in human non-metastatic NSCLC cell lines. In NSCLC tumor samples from 123 patients,...
07:00 , Aug 19, 2010 |  BC Innovations  |  Targets & Mechanisms

Leukemia takes it up a NOTCH

The Notch pathway has been linked to aggressive growth in a range of tumor types but had not previously been considered a prime target for myeloid leukemia therapies. Separate American teams now have identified two...
07:00 , Aug 19, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Acute myeloid leukemia (AML); chronic myeloid leukemia (CML) Musashi homolog 2 (MSI2) A study in mice...
07:00 , Aug 5, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) Musashi homolog 2 (MSI2) Studies in cell culture and in mice suggest that...